Similarly, the upregulation of IL-16, a chemotactic cytokine [40], could attract immune cells to the tumour microenvironment, potentially enhancing anti-tumour responses, and IL-1β can promote immune cell activation [41], which may contribute to the therapeutic effects of AuNP-P3. The gene discussed is IL16; the disease is neoplasm.